-
2 weeks ago | 
endocrinenews.endocrine.org | Kelly Horvath |Derek Bagley |Mark Newman
With evidence proliferating that endocrine-disrupting chemicals (EDCs) affect thyroid hormone synthesis, transport, metabolism, and action; that gestational exposure to environmental thyroid hormone disruptors affects cognitive function; and that exposure in general increases thyroid cancer risk, one session at ENDO 2025 explores these deleterious effects and some of their proposed underlying mechanisms in detail.
-
1 month ago | 
endocrinenews.endocrine.org | Kelly Horvath |Derek Bagley |Mark Newman
This July, the year’s biggest event in endocrinology happens in San Francisco, Calif. Although every ENDO is special, ENDO 2025 holds special importance. With advances in science happening at possibly the fastest rate in history, this meeting is endocrinologists’ one-stop shop for keeping up with progress and understanding how it will shape the future of endocrinology, an otherwise daunting task.
-
Jan 24, 2025 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
Olfactive Biosolutions was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in U.S. patent US 12,171,727 B1 dated Dec. 24, 2024, Compositions and Methods for Treating Endocrine Diseases and Disorders. The patent specifically relates to oral formulations of natural food molecules for treating diabetes mellitus and obesity by modulating ectopic olfactory, taste and related receptor activity.
-
Dec 6, 2024 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
On December 4, Amylyx announced the design of its pivotal Phase 3 LUCIDITY clinical trial for avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, for the treatment of post-bariatric hypoglycemia (PBH). LUCIDITY is designed to evaluate the FDA-agreed upon primary outcome of reduction in hypoglycemia events and to have similar inclusion and exclusion criteria to the previous Phase 2 trials of avexitide in PBH.
-
Nov 20, 2024 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
Research presented at ENDO 2024 in June shed more light on new or overlooked effects — mostly good — of medications prescribed to combat diabetes, such as GLP-1 receptor agonists, SGLT2 inhibitors, and DPP4 inhibitors. Spoiler alert: the GLP-1 receptor agonists may be emerging as the best in show.
-
Nov 14, 2024 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
According to the World Health Organization, more than half a billion people worldwide are living with diabetes, and most of those live in low- and middle-income countries, including Latin America, where the prevalence rate is higher than the global prevalence rate and projected to increase dramatically.
-
Nov 13, 2024 | 
endocrinenews.endocrine.org | Eric Seaborg |Kelly Horvath |Derek Bagley |Mark Newman
GLP-1 agonists are a cultural phenomenon. Celebrities and social media influencers hyping the drugs’ weight-loss success has led to demand outstripping supply, resulting in shortages for some patients who could benefit the most. High costs and limited insurance coverage have led patients to look for more affordable alternative sources. This success and notoriety have opened an attractive opportunity for imitators and quick-buck artists.
-
Nov 1, 2024 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
On October 29, a potentially major advancement for type 1 diabetes treatment was announced by the University of Miami Diabetes Research Institute (UM-DRI), in collaboration with the University of Chicago, regarding the pioneering the use of Tegoprubart (Eledon Pharmaceuticals, Irvine, Calif.), a novel anti-CD40L antibody, as an alternative to Tacrolimus in islet transplantation.
-
Jul 19, 2024 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
On July 17, Genentech, a member of the Roche Group, announced positive topline results from two arms of an ongoing multi-part Phase I clinical trial for CT-996, an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
-
Jun 28, 2024 | 
endocrinenews.endocrine.org | Kelly Horvath |Mark Newman
Morrisville, N.C.- based Metabolon, Inc., has received a grant from the National Institutes of Health (NIH) to develop an innovative product aimed at better monitoring and predicting the conversion of preclinical asymptomatic type 1 diabetes to clinical symptomatic, insulin-dependent type 1 diabetes. Over 3 million people in the United States live with type 1 diabetes.
